Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC of FOLFOX vs Sorafenib in TACE-Refractory HCC
NCT03722498Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2018
- Primary completion
- Mar 2021
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-free survival at 12 months. Planned start Jun 2018; status: withdrawn.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03722498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722498.